Olngenra 5 Tablet contains Olanzapine 5 mg, an atypical antipsychotic agent primarily used in the management of schizophrenia and bipolar disorder. Olanzapine exerts its therapeutic effects by modulating the activity of various neurotransmitter receptors in the brain, notably antagonizing dopamine D2 and serotonin 5-HT2A receptors, which helps in restoring the chemical balance associated with psychotic symptoms. This medication is indicated for the treatment of acute and chronic schizophrenia, bipolar mania, and as maintenance therapy to prevent relapse in bipolar disorder. Olngenra 5 Tablet is effective in reducing hallucinations, delusions, mood swings, and agitation, thereby improving patient functionality and quality of life. The recommended dosage should be individualized based on clinical response and tolerability, with close monitoring for adverse effects such as sedation, weight gain, metabolic changes, and extrapyramidal symptoms. Caution is advised in patients with a history of cardiovascular disease, diabetes, or hepatic impairment. Regular follow-up and laboratory assessments are essential to ensure safety and efficacy. Olngenra 5 Tablet should be used under strict medical supervision, and abrupt discontinuation is discouraged to prevent withdrawal symptoms or relapse.